An α1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia

Hypertension Research

Volumn 29, Issue 10, 2006, Pages 805-811

  Ihara, Shunichi ^a   Shimamoto, Ken ^a   Watanabe, Hirota ^a   Sakai, Rieko ^a   Kawana, Masatoshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

1 receptor blocker; Hypertension; Leptin; Obesity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; SULFONYLUREA; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG DOSE INCREASE; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; HYPERLEPTINEMIA; INSULIN RESISTANCE; MALE; OBESITY; RISK FACTOR; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; DRUG EFFECT; HYPERTENSION; MIDDLE AGED;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; DELAYED-ACTION PREPARATIONS; FATTY ACIDS, NONESTERIFIED; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1; TREATMENT OUTCOME;

EID: 33751572848     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.805     Document Type: Article

References (51)

1. Adami GF, Papadia F, Carlini F, et al: Effect of biliopancreatic diversion on hypertension in severely obese patients. Hypertens Res 2005; 28: 119-123.
2. Moinat M, Deng C, Muzzin P, et al: Modulation of obese gene expression in rat brown and white adipose tissues. FEBS Lett 1995; 373: 131-134.
3. Tartagia LA, Dembski M, Weng X, et al: Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
4. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1996; 395: 763-770.
5. Ogawa Y, Masuzaki H, Isse N, et al: Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. J Clin Invest 1995; 96: 1647-1652.
6. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P: Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994; 89: 2634-2640.
7. Lean ME: Brown adipose tissue in humans. Proc Nutr Soc 1989; 48: 243-256.
8. Rehnmark S, Kopecky J, Jacobsson A, et al: Brown adipocytes differentiated in vitro can express the gene for the uncoupling protein thermogenin: effects of hypothyroidism and norepinephrine. Exp Cell Res 1989; 182: 75-83.
9. Satoh N, Ogawa Y, Katsuura G, et al: Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 1999; 48: 1787-1793.
10. Friedman JM: Obesity in the new millennium. Nature 2000; 404: 632-634.
11. Wang MY, Lee Y, Unger RH: Novel form of lipolysis induced by leptin. J Biol Chem 1999; 274: 17541-17544.
12. Haynes WG, Mogan DA, Walsh SA, Wark AL, Sivitz WI: Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-278.
13. Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-414.
14. Casto RM, Vaness JM, Overton JM: Effect of central leptin administration on blood pressure in normotensive rats. Neurosci Lett 1998; 246: 29-32.
15. Ogawa Y, Masuzaki H, Hosoda K, et al: Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999; 48: 1822-1829.
16. Masuzaki H, Ogawa Y, Aizawa-Abe M, et al: Glucose metabolism and insulin sensitivity in transgenic mice over-expressing leptin with lethal yellow agouti mutation: usefulness of leptin for treatment of obesity-associated diabetes. Diabetes 1999; 48: 1615-1622.
17. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243-1252.
18. Kaushik RM, Mahajan SK, Rajesh V, Kaushik R: Stress profile in essential hypertension. Hypertens Res 2004; 27: 619-624.
19. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001; 14: 103S-115S.
20. Hosoda K, Masuzaki H, Ogawa Y, et al: Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 1996; 221: 234-239.
21. Agata J, Masuda A, Takada M, et al: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-1174.
22. Leyva F, Goldsland IF, Ghatei M, et al: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Thromb Vasc Biol 1998; 18: 928-933.
23. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
24. Maffei M, Halaas J, Ravussin E, et al: Leptin levels in humans and rodents: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
25. Lu H, Duanmu Z, Houck C, Jen KC, Buison A, Dunbar JC: Obesity due to a high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Res Bull 1998; 47: 331-335.
26. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI: The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51: 439-442.
27. Paolisso G, Taglimonte MR, Galderisi M, et al: Plasma leptin is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999; 34: 1047-1052.
28. Söderberg S, Ahren B, Stegmayr B, et al: Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999; 30: 328-337.
29. Söderberg S, Ahren B, Jansson JH, et al: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 426: 409-418.
30. Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program - Adult Treatment Panel III to Japanese men - the Tanno and Sobetsu study. Hypertens Res 2005; 28: 203-208.
31. Fujiwara T, Saitoh S, Takagi S, et al: Development and progression of atherosclerotic disease in relation to insulin resistance and hyperinsulinemia. Hypertens Res 2005; 28: 665-670.
32. Ishizuka N, Ishizaki Y, Toda E, er al: Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005; 28: 27-34.
33. Bönner G, Schmieder R, Chrosch R, Weidinger G: Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension. Cardiovasc Drugs Ther 1997; 11: 21-26.
34. 1-blocker (bunazosin). Am J Hypertens 1992; 5: 869-874.
35. 1-blocker bunazosin for lipid metabolism in rats. Akita J Med 1992; 19: 487-502.
36. Matsunaga A, Hidaka H, Sasaki J, Arakawa K: Bunazosin enhances receptor-mediated endocytosis of low-density lipoproteins. Artery 1992; 19: 307-317.
37. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.
38. Giorda C, Appendino M: Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism 1993; 42: 1440-1442.
39. Fernandez-Real JM, Gutierrez C, Vendrell J, et al: Polymorphism of the tumor necrosis factor-α receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 23: 831-837.
40. Mantzoros CS: The role of leptin in human obesity and disease; a review of current evidence. Ann Intern Med 1999; 130: 671-680.
41. Zhou YT, Wang ZW, Higa M, Newgard CB, Unger RH: Reversing adipocyte differentiation; implications for treatment of obesity. Proc Natl Acad Sci U S A 1999; 96: 2391-2395.
42. Saladin R, De Vos P, Guerre-Millo M, et al: Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-529.
43. Boden G, Chen X, Kolaczynski JW, Polansky M: Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997; 100: 1107-1113.
44. Müller G, Ertl J, Gerl M, Preibisch G: Leptin impairs metabolic action of insulin in isolated rat adipocytes. J Biol Chem 1997; 272: 10585-10593.
45. Kim-Motoyama H, Yamaguchi T, Katakura T, et al: Serum leptin levels are associated with hyperinsulinemia independent of body mass index, but not with visceral obesity. Biochem Biophys Res Commun 1997; 239: 340-344.
46. McGarry JD, Dobbins RL: Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
47. Greco AV, Mingrone G, Vettor R, et al: Lowering of circulating free fatty acid levels and reduced expression of leptin in white adipose tissue in postobesity status. J Invest Med 2002; 50: 207-213.
48. Heptull R, Smitten A, Teague B, Tamborlane WV, Ma YZ, Caprio S: Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J Clin Endocrinol Metab 2001; 86: 90-96.
49. Merwe MT, Panz VR, Crowther NJ, et al: Free fatty acids and insulin levels-relationship to leptin levels and body composition in various patient groups from South Africa. Int J Obes 1999; 23: 909-917.
50. Stefan N, Fritsche A, Häring H, Stumvoll M: Acute stimulation of leptin concentrations in humans during hyperglycemia. Int J Obes 2001; 25: 138-142.
51. Ueshiba H, Miyachi Y: Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35: 532-536.